Description: ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.
Home Page: www.chitogenx.com
16667 Hymus Boulevard
Kirkland,
QC
H9H 4R9
Canada
Phone:
514 261 4735
Officers
| Name | Title |
|---|---|
| Mr. Pierre Laurin B.Sc.Pharm., M.Sc. | Interim CEO & Chairman |
| Mr. Guy-Paul Allard | VP of Legal Affairs & Corporate Secretary |
| Dr. Jonathan Sackier | Senior Vice President of Medical Affairs |
| Mr. Frédéric Dumais | Director of Communications & Investor Relations |
| Mr. Benedek Simo | Controller |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | January |
| Full Time Employees: | 0 |